Partruvix (pamiparib) / BeOne Medicines - LARVOL DELTA

Drug combination discovery assisted by AI and untargeted metabolomics: pamiparib and anlotinib synergistic potentiation for ovarian cancer treatment. (PubMed, Front Pharmacol) - "In vivo, significant downregulation of p-PI3K, p-Akt, Bcl-2, and HIF1-α, and upregulation of BAX protein expression confirmed that the mechanism of action of combination therapy is related to PI3K/Akt pathway. The combination of PAM and ANL was more effective than monotherapy for treating ovarian cancer and holds potential to become a new therapeutic approach for ovarian cancer."

IO biomarker • Journal • Oncology • Ovarian Cancer • Solid Tumor • ANXA5 • BAX • BCL2 • HIF1A

Broad-spectrum anti-influenza activity of the NMPA-approved drug Pamiparib is uncovered by virtual docking to the evolutionarily conserved domain of IAV-M2 protein. (PubMed, Bioorg Med Chem) - "In addition, pamiparib suppresses effectively viral infection in vivo. Ultimately, this study verifies that antiviral drugs designed to target the evolutionarily conserved regions of the influenza virus M2 protein indeed possess broad-spectrum antiviral activity across different strains."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer. (PubMed, Pharmacol Res) - "The FDA has approved four PARP inhibitors (olaparib, rucaparib, niraparib, and talazoparib) for the treatment of ovarian, breast, prostate, and pancreatic cancer...The Chinese NMPA has approved three PARP antagonists (fuzuloparib, pamiparib, senaparib) for the treatment of ovarian cancer. All seven of these drugs are orally bioavailable and fall within the criteria of Lipinski's rule of five. Drug resistance develops in most PARP-inhibitor-treated cancer patients within one or two years."

Journal • Review • Breast Cancer • Genito-urinary Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Solid Tumor • BRCA1 • BRCA2 • HRD

A prospective, randomized, open-label, controlled clinical study comparing ivosimod combined with chemotherapy versus pamiparib combined with chemotherapy as neoadjuvant therapy for NSCLC (ChiCTR) - P2 | N=168 | Recruiting | Sponsor: Peking University People's Hospital; Peking University People's Hospital

New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma. (PubMed, Curr Oncol) - P1/2 | "Treatment-emergent cytopenia was manageable and reversible with dose reductions/interruptions. Combination regimens demonstrated antitumor activity."

Journal • P1/2 data • Brain Cancer • Glioblastoma • Hematological Disorders • Oncology • Solid Tumor • MGMT

Quality of Life Analysis in Patients with High-Risk Localized Prostate Cancer Receiving Neoadjuvant Pamiparib plus Abiraterone and ADT: A Prospective Study [WITHDRAWN] (ESMO 2025) - No abstract available

Clinical • HEOR • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Efficacy and safety profiles of PARP inhibitors in Chinese patients with metastatic breast cancer: A multi-center real-world study (ESMO 2025) - "Results 62 MBC patients treated with olaparib (n = 55), talazoparib (n = 4), pamiparib (n = 2) and fluzoparib (n = 1) were analyzed. Conclusions PARPis showed promising PFS and tolerable toxicity in the real-word treatment of Chinese patients with metastatic breast cancer. Legal entity responsible for the study The authors."

Clinical • Metastases • Real-world • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BRCA • BRCA1 • BRCA2 • CDK12 • CHEK1 • HER-2 • HRD • PALB2 • RAD51C

Phase I/II and Window-of-Opportunity Study of Pamiparib and Metronomic Temozolomide for Recurrent IDH Mutant Gliomas. (PubMed, Neuro Oncol) - "Pamiparib appeared to achieve sufficient pharmacologically active concentrations in both enhancing and non-enhancing tumors. While some patients achieved prolonged progression-free survival, combination with temozolomide did not produce a meaningful ORR in IDHmt recurrent gliomas. Cumulative hematologic toxicity was substantial and impacted long-term tolerability."

Journal • P1/2 data • Brain Cancer • Glioma • Hematological Disorders • Neutropenia • Oncology • Solid Tumor

Molecular and morphological features of blood vessels in tumour margin regions of glioblastoma are distinct from tumour core and normal brain, and drug delivery is reduced (EANO 2025) - "Material and Longitudinal measurement (11 samples, 8 hours) of free extracellular levels of PARP inhibitors pamiparib (high brain penetrance) and olaparib (low penetrance) was performed by microdialysis in tumour core, margin and contralateral brain in GBM xenografted CD1 nude mice. Dynamic microdialysis studies show that the PARP inhibitor olaparib penetrates tumour margin regions at lower concentrations than core. Towards understanding this effect, multiplex IHC has revealed two types of vessels in margin regions: almost 50% resembled normal brain vessels but with altered levels of claudin-5, while the others shared morphological properties with a subpopulation of tumour core vessels."

Brain Cancer • Glioblastoma • Oncology • Solid Tumor • CD31 • CLDN5 • PDGFRB • PECAM1

Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma (Multidisciplinary Digital Publishing Institute) - "Disease control and objective response rates were 67.9% and 11.3%, respectively, for treatment-naïve patients in the dose-escalation and -expansion studies, and 40.9% and 13.6%, respectively, for recurrent/refractory patients. Median overall survival for treatment-naïve MGMT unmethylated patients was 12.8 months and 7.3 months for recurrent/refractory MGMT methylated and unmethylated patients."

P1/2 data • Glioblastoma

A case report of advanced small intestinal stromal tumor with KIT gene mutation and BRCA2 deletion after multi-line treatments. (PubMed, Front Oncol) - "After initial surgery and adjuvant imatinib, the tumor recurred. Through comprehensive analysis of gene mutation profiles (KIT and HRR gene mutations, including BRCA2), a combination therapy of fluzoparib, pamiparib, and ripretinib was administered, stabilizing the patient's condition with significant efficacy. This case highlights the importance of genetic testing and personalized targeted treatment strategies for gastrointestinal stromal tumor (GIST) patients."

Journal • Gastrointestinal Cancer • Gastrointestinal Stromal Tumor • Oncology • Sarcoma • BRCA2 • HRD • KIT

A novel 18F-labeled brain penetrant PET ligand for imaging poly(ADP-ribose) polymerase-1 (SNMMI 2025) - "Blocking studies with AZD9574, Olaparib, Rucaparib, Veliparib, and Pamiparib significantly reduced intracellular radiotracer uptake, while no significant reduction was observed with UPF-1035, a PARP2-specific inhibitor (Fig. The radiotracer 18F-AZD9574 was synthesized following a previously established protocol (Fig. 1A). Western blot analysis confirmed substantial PARP1 expression in the U87-MG (glioblastoma), 22Rv1 (prostate), PSN-1 (pancreatic), MDA-MB-436 (breast), and MDA-MB-231 (breast) cancer cell lines (Fig."

Brain Cancer • Breast Cancer • Glioblastoma • Oncology • Pancreatic Cancer • Solid Tumor • PARP1 • PARP2

Imaging Parthanatos in Animal Models of Parkinson’s disease (SNMMI 2025) - "In vitro PARP1 immunostaining and autoradiography (AR) using the PARP radioligand [18F]BGB290 were used to compare with the PET imaging results... Immunostaining revealed elevated PARP1 expression in the striatum of the PFF-injected mice (Figure 1A). The PET imaging showed higher SUV at the ipsilateral (Ipsi) striatum of the PFF-injected mice compared to the contralateral striatum, while the hippocampus showed no significant changes between the two groups, consistent with the spreading pattern of α-syn in this animal model. Increased DVRs were observed in striatum-Ipsi (42%, p < 0.05) and the whole brain (20%, p < 0.05)."

Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

SPRING: Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Peking University Shenzhen Hospital

Biomarker • New P2 trial • Oncology

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors (clinicaltrials.gov) - P1 | N=44 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Jun 2025 ➔ Jun 2026 | Trial primary completion date: Jun 2025 ➔ Jun 2026

Trial completion date • Trial primary completion date • Oncology • Solid Tumor • ARID1A • BRCA1 • BRCA2 • CHEK1 • CHEK2 • EMSY • PARP1 • PTEN • RAD50

A prospective, single-arm, phase 2 trial exploring the use of pamiparib combined with surufatinib as neoadjuvant therapy for advanced, unresectable ovarian cancer (PASSION). (ASCO 2025) - P2 | "Pamiparib and surufatinib show promising efficacy and manageable toxicity in advanced OC, reshaping the tumor microenvironment and promoting immune infiltration."

Clinical • Metastases • P2 data • Anemia • Leukopenia • Neutropenia • Oncology • Ovarian Cancer • Solid Tumor • CSF1R • FGFR1 • FLT1

Neoadjuvant pamiparib in patients with newly diagnosed advanced ovarian cancer: A single-arm, prospective phase II trial. (ASCO 2025) - "The treatment regimen comprises paclitaxel (175 mg/m^2, Day 1) and carboplatin (AUC 5, Day 2) every three weeks for up to six cycles. The preliminary results suggest that the addition of pamiparib to neoadjuvant chemotherapy plus bevacizumab offers promising efficacy and acceptable safety in newly diagnosed advanced ovarian cancer. Further data will be provided as the study progresses."

Clinical • Metastases • P2 data • Anemia • Endometrial Cancer • Fallopian Tube Cancer • Leukopenia • Neutropenia • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • Thrombocytopenia • MUC16

BRIGHT: Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer (clinicaltrials.gov) - P2 | N=108 | Completed | Sponsor: Tongji Hospital | Not yet recruiting ➔ Completed | N=160 ➔ 108 | Trial completion date: Dec 2027 ➔ Feb 2025 | Trial primary completion date: Jun 2024 ➔ Feb 2025

Biomarker • Enrollment change • Platinum resistant • Trial completion • Trial completion date • Trial primary completion date • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRCA1

BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - P3 | N=430 | Enrolling by invitation | Sponsor: BeiGene | N=300 ➔ 430

Enrollment change • Oncology • Solid Tumor

Research Progress of M6A Methylation Modification in Immunotherapy of Colorectal Cancer. (PubMed, Curr Cancer Drug Targets) - "This review has sys-tematically summarized the latest clinical application of six authorized PARPi, including olaparib, rucaparib, niraparib, talazoparib, fuzuloparib and pamiparib, in monotherapy and combination therapies with chemotherapy, radiotherapy, and immunotherapy, in different kinds of cancer. Furthermore, probable challenges in PARPi application and drug resistance mechanisms have also been discussed. Despite these challenges, further development of new PARP1 inhibitors appears promising as a valuable approach to cancer treatment."

Journal • Colorectal Cancer • Oncology • Solid Tumor

Population Pharmacokinetic Modeling of Total and Unbound Pamiparib in Glioblastoma Patients: Insights into Drug Disposition and Dosing Optimization. (PubMed, Pharmaceutics) - " The total and unbound pamiparib plasma PK are well characterized by a linear one-compartment model, with creatinine clearance as the significant covariate on V/F. Model simulations support further clinical investigation into dose reduction to optimize the benefit-to-risk ratio of pamiparib, particularly in combination therapies."

Journal • PK/PD data • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Engaging an engineered PARP-2 catalytic domain mutant to solve the complex structures harboring approved drugs for structure analyses. (PubMed, Bioorg Chem) - "Consequently, the complex structures of Fluzoparib, Pamiparib, Rucaparib, and Niraparib within PARP-2 were achieved. It suggested that the residues adjacent to Asp766 in the HD and ASL domains and the αJ-αF and ASL-αD interfaces were closely related to the selectivity and trapping mechanism. These results would provide some insights for the design and development of novel PARP-1/2 inhibitors with improved pharmacodynamic properties."

Journal • Oncology • PARP1 • PARP2

Pamiparib-induced replication stress augments the efficacy of temozolomide in GBM PDX models (AACR 2025) - "In conclusion, pamiparib enhances TMZ efficacy in a subset of primary GBM. While further in vivo validation is needed, TLS deficiency may be a key determinant of pamiparib-mediated sensitization."

Clinical • Glioblastoma • Oncology • MGMT • MRE11A

Biomarker-driven targeted therapy in patients with recurrent platinum-resistant epithelial ovarian cancer (BRIGHT): protocol for an open-label, multicenter, umbrella study. (PubMed, Int J Gynecol Cancer) - P2 | "To evaluate the efficacy and safety of biomarker-driven combinatorial therapies of pamiparib, tislelizumab, bevacizumab, and nab-paclitaxel in platinum-resistant, recurrent ovarian cancer. Recruitment is estimated to be completed by 2024 and results may be published by 2027. ClinicalTrials.gov: NCT05044871."

Biomarker • Clinical protocol • IO biomarker • Journal • Platinum resistant • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Ovarian Clear Cell Cancer • Solid Tumor • BRCA1 • BRCA2 • CD8

BGB-290-302: Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - P3 | N=224 | Active, not recruiting | Sponsor: BeiGene | Trial completion date: Jun 2026 ➔ Jun 2027 | Trial primary completion date: Jun 2025 ➔ Jun 2026

Platinum sensitive • Trial completion date • Trial primary completion date • Oncology • Ovarian Cancer • Solid Tumor